Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.

    Thumbnail
    Download
    Citations
    Altmetric
    Author
    McClure, T; Cui, W; Asadi, K; John, T; Testro, A
    Date
    2020-09
    Source Title
    BMJ Open Gastroenterology
    Publisher
    BMJ
    University of Melbourne Author/s
    Testro, Adam
    Affiliation
    Medical Education
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    McClure, T., Cui, W., Asadi, K., John, T. & Testro, A. (2020). Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.. BMJ Open Gastroenterol, 7 (1), pp.e000487-e000487. https://doi.org/10.1136/bmjgast-2020-000487.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/252197
    DOI
    10.1136/bmjgast-2020-000487
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867
    Abstract
    Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.

    Export Reference in RIS Format     

    Collections